Syngene's multi-year agreement with GSK to focus on research: Jonathan Hunt

Syngene International has signed a R&D agreement with British drug giant GSK.

Throwing more light on the partnership Jonathan Hunt, CEO, Syngene International said it is a multi-year agreement. It is a discovery research partnership where scientist of both the companies will work together to help GSK accelerate their research projects and bring in new medicine for patients.

“It is under the discovery space, where scientist will look for new breakthroughs in innovative medicines, so that they can go into the next phase of clinical testing,” said Hunt.

It is in areas of chemical synthesis, medicinal chemistry, computational chemistry, said Hunt.